Citations

Clear

1446 citation(s) found for "Howard, F".

Abstract A27: Redefining the role of Notch in acinar to ductal metaplasia
Halbrook, Christopher J. , Crawford, Howard C.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: A27-A27

10.1158/1538-7445.panca2014-a27 Get It

Abstract The EGFR and Notch signaling pathways have been widely implicated in relation to both chronic pancreatitis and pancreatic ductal adenocarcinoma in humans, however the link between the two pathways has remained obscure. Acinar to ductal metaplasia (ADM,) a phenomenon where acinar cells undergo a morphological change and begin expressing markers normally found only in ductal cells while losing markers typical of acinar cells, has been linked to both the Notch and EGFR signaling pathways. ADM is highly proliferative with the potential to develop into pancreatic intraepithelial neoplasia, a precursor lesion to pancreatic cancer. Recently we and others have shown that genetic ablation of EGFR in the pancreas effectively prevents acinar to ductal metaplasia in cerulein model of pancreatitis in mice, and prevents tumorigenesis driven by oncogenic Kras. Additionally, we have found that acinar cells harvested from EGFRf/f;Ptf1aCre/+ mice (EKO) mice are resistant to ADM in vitro upon cerulein treatment, or by the expression of oncogenic Kras. Activation of EGFR by treatment of WT collagen embedded acinar cell explants with the EGFR ligand TGF-α has previously been shown to induce ADM in a manner requiring Notch pathway activation. Furthermore, it has also been demonstrated that expression of Notch2 intracellular domain (N2ICD) is sufficient to induce ADM in WT acinar cells. To directly investigate the relationship of the EGFR, Kras, and Notch signaling pathways in ADM, we examined the effect of Notch signaling in acinar cells harvested from EKO mice. Interestingly, these acinar cells fail to transdifferentiate in vitro upon transduction of N2ICD in 3D culture; however the transdifferentiation event can be rescued by co-expression of oncogenic Kras with N2ICD in acinar cells lacking EGFR. These results indicate that EGFR is important in Notch induced ADM, however there are other pathways that possibly can be utilized by acinar cells expressing oncogenic Kras to drive ADM. Citation Format: Christopher J. Halbrook, Howard C. Crawford. Redefining the role of Notch in acinar to ductal metaplasia. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A27.
Abstract A04: PI3K regulation of RAC1 is required for Kras-induced pancreatic tumorigenesis
Takeuchi, Kenneth K., Wu, Claire , Halbrook, Christopher J. , Carpenter, Eileen S. , Lin, Richard Z. , Crawford, Howard C.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: A04-A04

10.1158/1538-7445.panca2014-a04 Get It

Abstract Nearly all pancreatic ductal adenocarcinomas are caused by oncogenic mutations in the KRAS gene. Pharmacological inhibition of mutant KRAS has thus far been unsuccessful in the clinical setting, precipitating a need to understand the pathways downstream of KRAS which may prove more easily targeted with small molecule inhibitors. Here we show that PI3K p110α is absolutely required for pancreatic tumorigenesis while p110β is dispensable for this process. Surprisingly, ablation of p110α does not impair the ability of KRAS to activate AKT, demonstrating that AKT activation is not sufficient for transformation. Instead we find that p110α is required for robust activation of RAC1, a small GTPase required for pancreatic metaplasia. Consistent with this, our data show that p110α is necessary for regulating epithelial expression and activation of RAC-GEFs including Vav1, Tiam1 and Ect2. Ultimately, these results define the mechanistic role of p110α in pancreatic tumorigenesis and suggest selective inhibition of this PI3K isoform as a promising therapeutic approach to treating patients with pancreas cancer. Citation Format: Kenneth K. Takeuchi, Eileen Carpenter, Claire Wu, Christopher J. Halbrook, Richard Z. Lin, Howard C. Crawford. PI3K regulation of RAC1 is required for Kras-induced pancreatic tumorigenesis. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A04.
Recurrent duplications of 17q12 associated with variable phenotypes
Mitchell, Elyse, Douglas, Andrew G. L. , Kjaegaard, Susanne, Callewaert, Bert , Janssens, Sandra , Yuen, Amy Lawson, Skinner, Cindy , Failla, Pinella , Alberti, A , Avola, Emanuela , Fichera, Marco , Kibæk, Maria, Digilio, M. Cristina , Hannibal, Mark , Hollander, Nicolette S. den , Bizzarri, Veronica, Renieri, Alessandra , Mencarelli, Maria Antonietta , Fitzgerald, Tomas , Piazzolla, Serena, Oudenhove, Elke Van , Romano, Corrado , Schwartz, Charles E. , Rajan, Diana, Crolla, John A., Carter, Nigel, Hodge, Jennelle C. , Vanlander, Arnaud Vincent , Eichler, Evan E , Slavotinek, Anne , Escobar, Luis Fernando , Mefford, Heather C. , Callewaert, Bert , Renieri, Alessandra

Mayo Clinic

American Journal of Medical Genetics Part A | September 30, 2015 | Volume: 167 | Issue: 12 | Pages: 3038-3045

10.1002/ajmg.a.37351 | PMID 26420380 Get It

The ability to identify the clinical nature of the recurrent duplication of chromosome 17q12 has been limited by its rarity and the diverse range of phenotypes associated with this genomic change. In order to further define the clinical features of affected patients, detailed clinical information was collected in the largest series to date (30 patients and 2 of their siblings) through a multi‐institutional collaborative effort. The majority of patients presented with developmental delays varying from mild to severe. Though dysmorphic features were commonly reported, patients do not have consistent and recognizable features. Cardiac, ophthalmologic, growth, behavioral, and other abnormalities were each present in a subset of patients. The newly associated features potentially resulting from 17q12 duplication include height and weight above the 95th percentile, cataracts, microphthalmia, coloboma, astigmatism, tracheomalacia, cutaneous mosaicism, pectus excavatum, scoliosis, hypermobility, hypospadias, diverticulum of Kommerell, pyloric stenosis, and pseudohypoparathryoidism. The majority of duplications were inherited with some carrier parents reporting learning disabilities or microcephaly. We identified additional, potentially contributory copy number changes in a subset of patients, including one patient each with 16p11.2 deletion and 15q13.3 deletion. Our data further define and expand the clinical spectrum associated with duplications of 17q12 and provide support for the role of genomic modifiers contributing to phenotypic variability. © 2015 Wiley Periodicals, Inc.
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
Arai, Sally , Pidala, Joseph, Pusic, Iskra , Chai, Xiaoyu , Khera, Nandita , Palmer, Jeanne , Chen, George L. , Jagasia, Madan , Mayer, Sebastian , Wood, William A. , Hyun, Teresa S. , Inamoto, Yoshihiro , Storer, Barry E. , Shulman, Howard M., Sarantopoulos, Stefanie , Lee, Stephanie J. , Jaglowski, Samantha , Green, Michael , Miklos, David B. , Martin, Paul J. , Flowers, Mary E.D. , Chen, George , Lee, Stephanie J , Wood, William A

Mayo Clinic

Clinical Cancer Research | September 16, 2015 | Volume: 22 | Issue: 2 | Pages: 319-327

10.1158/1078-0432.ccr-15-1443 | PMID 26378033 Get It

Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrent malignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%–43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%–44%) randomized to rituximab. Six (17%; 95% CI, 7%–34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%–29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P = 0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab. Clin Cancer Res; 22(2); 319–27. ©2015 AACR.
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Xia, Shu , Du, Meijun , Nandy, Debashis, Yuan, Tiezheng , Guo, Yongchen, Tschannen, Michael, See, William A., Kilari, Deepak , Wang, Xuexia , Hovey, Raymond , Huang, Chiang‐Ching , Kohli, Manish , Dittmar, Rachel L. , Lee, Adam, Wang, Yuan , Worthey, Elizabeth A. , Jacob, Howard J. , Wang, Liang

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 18 | Pages: 16411-16421

10.18632/oncotarget.3845 | PMID 25915538 Get It

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Feng, Tom , Sun, Xizi, Howard, Lauren E. , Vidal, Adriana C. , Gaines, Alexis R., Moreira, Daniel M. , Castro‐Santamaria, Ramiro , Andriole, Gerald L. , Freedland, Stephen J. , Howard, Lauren E

Mayo Clinic

Cancer Prevention Research | September 10, 2015 | Volume: 8 | Issue: 11 | Pages: 1055-1060

10.1158/1940-6207.capr-15-0141 | PMID 26353947 Get It

Abstract The role of metformin in prostate cancer chemoprevention remains unclear. REDUCE, which followed biopsy-negative men with protocol-dictated PSA-independent biopsies at 2- and 4-years, provides an opportunity to evaluate the link between metformin use and prostate cancer diagnosis with minimal confounding from screening biases. In diabetic men from REDUCE, we tested the association between metformin use, use of other antidiabetic medications, versus no antidiabetic medication use, and prostate cancer diagnosis as well as prostate cancer grade (low-grade Gleason 4–6 and high-grade Gleason 7–10) using logistic regression. Of the 540 diabetic men with complete data, 205 (38%) did not report use of any antidiabetic medications, 141 (26%) reported use of at least one antidiabetic medication other than metformin, and 194 (36%) reported use of metformin. During the 4-year study, 122 men (23%) were diagnosed with prostate cancer. After adjusting for various clinical and demographic characteristics, we found that metformin use was not significantly associated with total (OR, 1.19; P = 0.50), low- (OR, 1.01; P = 0.96), or high-grade (OR, 1.83; P = 0.19) prostate cancer diagnosis. Likewise, there was no significant association between the use of non-metformin antidiabetic medications and prostate cancer risk in both crude (OR, 1.02; P = 0.95) and multivariable analysis (OR, 0.85; P = 0.56). Furthermore, the interactions between antidiabetic medication use and BMI, geographic location, coronary artery disease, smoking, and treatment group were not significant (all P > 0.05). Among diabetic men with a negative prestudy biopsy who all underwent biopsies largely independent of PSA, metformin use was not associated with reduced risk of prostate cancer diagnosis. Cancer Prev Res; 8(11); 1055–60. ©2015 AACR.
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium
Laurent, Louise C. , Abdel‐Mageed, Asim B. , Adelson, P. David , Arango, Jorge , Balaj, Leonora , Breakefield, Xandra O., Carlson, Elizabeth, Majem, Blanca , Chen, Clark C. , Cocucci, Emanuele , Danielson, Kirsty , Courtright, Amanda, Das, Saumya , Enderle, Daniel , Ezrin, Alan M., Galas, David J. , Gandhi, Roopali, Huentelman, Matthew J. , Keuren‐Jensen, Kendall Van , Kalani, Yashar, Kim, Yong , Krichevsky, Anna M. , Lai, Charles Pin‐Kuang , Lal‐Nag, Madhu , Laurent, Clara D., Leonardo, Trevor R. , Malenica, Ivana , Mondal, Debasis , Nejad, Parham, Raffaı̈, Robert L. , Rubio, Renee, Skog, Johan , Spetzler, Robert, Sun, Jie , Tanrıverdi, Kahraman , Vickers, Kasey C. , Wang, Yaoyu, Weiner, Howard L. , Yeri, Ashish, Gould, Stephen J. , Breakefield, Xandra O. , Courtright-Lim, Amanda , Yan, Irene K. , Laurent, Louise C , Carter, Bob S. , Elmageed, Zakaria Y. Abd , Ferrer, Marc , Freedman, Jane E. , Li, Feng , Patel, Tushar , Wang, Liang , Wang, Yaoyu, Wei, Zhiyun , Wong, David T.

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.26533 | PMID 26320937 Get It

Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to progress in this field is the lack of robust and standardized methods for collection and processing of biofluids, separation of different types of exRNA‐containing particles and isolation and analysis of exRNAs. The Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first joint endeavour, we held a series of conference calls and in‐person meetings to survey the methods used among our members, placed them in the context of the current literature and used our findings to identify areas in which the identification of robust methodologies would promote rapid advancements in the exRNA field.
Extracellular RNAs: development as biomarkers of human disease
Das, Saumya , Freedman, Jane E. , Laurent, Louise C. , Hochberg, Fred H. , Keuren‐Jensen, Kendall Van , Huentelman, Matt , Spetzler, Robert, Arango, Jorge , Adelson, P. David , Weiner, Howard L. , Gandhi, Roopali, Putterman, Chaim , Saugstad, Julie A. , Quinn, Joseph F. , Patel, Tushar , Wong, David T. , Laurent, Louise C , Carter, Bob S. , Kalani, M. Yashar S. , Goilav, Béatrice , Saugstad, Julie A

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.27495 | PMID 26320940 Get It

Ten ongoing studies designed to test the possibility that extracellular RNAs may serve as biomarkers in human disease are described. These studies, funded by the NIH Common Fund Extracellular RNA Communication Program, examine diverse extracellular body fluids, including plasma, serum, urine and cerebrospinal fluid. The disorders studied include hepatic and gastric cancer, cardiovascular disease, chronic kidney disease, neurodegenerative disease, brain tumours, intracranial haemorrhage, multiple sclerosis and placental disorders. Progress to date and the plans for future studies are outlined.
Heart Rate and Ischemic Stroke: The Reasons for Geographic and Racial Differences in Stroke (Regards) Study
O’Neal, Wesley T. , Howard, Virginia J. , Howard, George , Soliman, Elsayed Z. , Qureshi, Waqas T , Judd, Suzanne E. , Meschia, James F. , Howard, Virginia J , Howard, George

Mayo Clinic

International Journal of Stroke | August 26, 2015 | Volume: 10 | Issue: 8 | Pages: 1229-1235

10.1111/ijs.12620 | PMID 26306564 Get It

Background The association between resting heart rate and ischemic stroke remains unclear. Aim To examine the association between resting heart rate and ischemic stroke. Methods A total of 24 730 participants (mean age: 64 ± 9·3 years; 59% women; 41% blacks) from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study who were free of stroke at the time of enrollment (2003–2007) were included in this analysis. Resting heart rate was determined from baseline electrocardiogram data. Heart rate was examined as a continuous variable per 10 bpm increase and also as a categorical variable using tertiles (<61 bpm, 61 to 70 bpm, and >70 bpm). First-time ischemic stroke events were identified during follow-up and adjudicated by physician review. Results Over a median follow-up of 7·6 years, a total of 646 ischemic strokes occurred. In a Cox regression model adjusted for socio-demographics, cardiovascular risk factors, and potential confounders, each 10 bpm increase in heart rate was associated with a 10% increase in the risk of ischemic stroke (hazard ratio = 1·10, 95% confidence interval = 1·02, 1·18). In the categorical model, an increased risk of ischemic stroke was observed for heart rates in the middle (hazard ratio = 1·29, 95% confidence interval = 1·06, 1·57) and upper (hazard ratio = 1·37, 95% confidence interval = 1·12, 1·67) tertiles compared with the lower tertile. The results were consistent when the analysis was stratified by age, gender, race, exercise habits, hypertension, and coronary heart disease. Conclusion In REGARDS, high resting heart rates were associated with an increased risk of ischemic stroke compared with low heart rates. Further research is needed to examine whether interventions aimed to reduce heart rate decrease stroke risk.